MALAT1 and prostate carcinoma: Wang et al. determined that enzalutamide resistant prostate cancer cell lines have increased levels of MALAT 1 and SF2 activity, whereas MALAT 1 may enhance AR-V7 splicing by forming a MALAT1-SF2 complex leading to enzalutamide resistance [125].